Comment on: “Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts” - 11/02/20
Doi : 10.1016/j.jaad.2019.09.086
Arash Taheri, MD a, b, ⁎ 
, Parisa Mansoori, MD c
, Parisa Mansoori, MD c a Vohra Wound Physicians, Atlanta, Georgia
b Hyperbaric Physicians of Georgia, Atlanta, Georgia
c Atlanta Dermatopathology, Atlanta, Georgia
∗Reprint requests: Arash Taheri, MD, HyperbaRXs Wound Clinic, Saint Joseph's Hospital, 5665 Peachtree Dunwoody Rd, Ste G10, Atlanta, GA 30342HyperbaRXs Wound ClinicSaint Joseph's Hospital5665 Peachtree Dunwoody Rd, Ste G10AtlantaGA30342
Il testo completo di questo articolo è disponibile in PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
© 2019
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 82 - N° 3
P. e101-e102 - marzo 2020 Ritorno al numero
Articolo precedente
- Reply to: “Re-evaluating the relationship between appointment nonattendance and appointment lead time”
- Sofia B. Chaudhry, Elaine Siegfried, Eric Armbrecht
- Reply to: “Comment on ‘Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts’”
- Ahmad Nofal, Ayman Marei, Al-shimaa M. Ibrahim, Eman Nofal, Manal Nabil
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?